CN109316552A - 一种治疗足癣的药物组合物 - Google Patents
一种治疗足癣的药物组合物 Download PDFInfo
- Publication number
- CN109316552A CN109316552A CN201811455140.2A CN201811455140A CN109316552A CN 109316552 A CN109316552 A CN 109316552A CN 201811455140 A CN201811455140 A CN 201811455140A CN 109316552 A CN109316552 A CN 109316552A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- tinea pedis
- composition according
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004647 tinea pedis Diseases 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241000218682 Pseudolarix amabilis Species 0.000 claims abstract description 15
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 15
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 15
- 229940037003 alum Drugs 0.000 claims abstract description 15
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 14
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 14
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 14
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 14
- 239000003429 antifungal agent Substances 0.000 claims abstract description 12
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 8
- 150000003852 triazoles Chemical class 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 7
- 229960001589 posaconazole Drugs 0.000 claims description 7
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 6
- 229940116229 borneol Drugs 0.000 claims description 6
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 6
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 4
- 229960004130 itraconazole Drugs 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 28
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000000306 recurrent effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000013011 mating Effects 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 210000003371 toe Anatomy 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001716 anti-fugal effect Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000002670 dry beriberi Diseases 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940042129 topical gel Drugs 0.000 description 2
- 229940041677 topical spray Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 208000002655 Foot Dermatoses Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗足癣的药物组合物,各个组份的质量份数之和为100份,由以下组份组成:唑类抗真菌药物0.5‑5份、土荆皮0.1‑10份、苦参0.1‑10份、黄精0.1‑10份、白鲜皮0.1‑5份、薄荷0.1‑5份、丁香0.1‑2份、艾叶0.1‑2份、明矾0.1‑2份,余量为辅料和水。在本发明中,实现了在抗真菌药物与中药共同配合作用下,对足癣能起到标本兼治的作用,尤其是在治疗复发性足癣有着显著的临床疗效,并具有制备简单、成本低的优点。
Description
技术领域
本发明涉及制药技术领域,尤其涉及一种治疗足癣的药物组合物。
背景技术
足癣是由真菌感染引起,其皮肤损害往往是先单侧(即单脚)发生,数周或数月后才感染到对侧。水疱主要出现在趾腹和趾侧,最常见于三四趾间,足底亦可出现,为深在性小水疱,可逐渐融合成大疱。足癣的皮肤损害有一特点,即边界清楚,可逐渐向外扩展。因病情发展或搔抓,可出现糜烂、渗液,甚或细菌感染,出现脓疱等。
足癣是由致病性真菌引起的足部皮肤病,具有传染性。足癣在全世界广为流行。在我国,足癣的发病率也相当高。人的足底和趾间没有皮脂腺,从而缺乏抑制皮肤丝状真菌的脂肪酸,生理防御机能较差,而这些部位的皮肤汗腺却很丰富,出汗比较多,加之空气流通性差、局部潮湿温暖,有利于真菌的生长。此外,足底部位皮肤角质层较厚,角质层中的角蛋白是真菌的丰富营养物质,有利于真菌的生长。
女性在妊娠期间,由于内分泌的变化,引起皮肤抵抗真菌感染的能力下降,易患足癣。肥胖者因趾间潮湿,汗液浸渍易患足癣。足部皮肤受外伤,破坏了皮肤的防御功能,也是诱发足癣的因素之一。糖尿病患者由于缺乏胰岛素导致物质代谢紊乱,皮肤含糖量增加导致抵抗力下降,也易患足癣。滥用抗生素,长期使用皮质类固醇激素和免疫抑制剂等,使皮肤正常菌群失调,也会增加足癣的易感性。
足癣在中医中被认为是因外感湿邪风毒,或饮食厚味所伤,积湿生热,流注腿脚而致病。中医认为足癣分为湿脚气与干脚气两种,湿脚气是寒湿下流造成的肿痛;而干脚气则是湿热下注造成的瘙痒,俗称是香港脚。对于这两种脚气的共性都是有湿,中医认为根本的原因是体内积湿许久,后由体湿而下注,从而引发足癣。不同的类型的足癣,其临床表现也不同,一个是肿痛,一个是瘙痒。对患者带来极大的不便与痛苦。
而现代医学研究则针对足癣的症状是根据类型划分的,不同类型足癣的症状是不同的,医学上通常将足癣分三型:糜烂型(表现为局部表皮角质层浸软发白。由于走动时不断摩擦表皮脱落,露出鲜红色糜烂面;严重者趾缝间、趾腹与足底交界处皮肤均可累及,瘙痒剧烈,多发于第3、4、5趾缝间。常见于多汗者)、水疱型(多发生在夏季,表现为趾间、足缘、足底出现米粒大小,深在性水疱,疏散或成群分布,疱壁较厚,内容清澈,不易破裂,相互融合形成多房性水疱,撕去疱壁,可见蜂窝状基底及鲜红色糜烂面,剧烈瘙痒)、角化型(症状是足跖、足缘、足跟部皮肤脚趾增厚、粗糙、脱屑,鳞屑成片状或小点状,反复脱落)。
目前,对足癣的治疗方式主要如下所示。
局部治疗:主要使用一些杀菌消炎的药物对局部进行浸泡或清洗(尤其是糜烂性),然后外涂(喷)抗真菌药物,如外用唑类、中成药膏剂等。该治疗方案对一般性的足癣效果确切,但是治疗反复性、顽固性足癣疗效不佳。并且由于一些药物往往刺激性较大,可能会带来二次感染。
全身治疗:短期口服抗真菌药物如伊曲康唑、氟康唑、特比奈芬等抗真菌药物,单纯使用这些药物由于药物很难到达皮肤的角质层,所以往往治疗效果不够理想,并且副作用较大,仅能短期口服治疗,并且需要定期监控肝功,如发现肝功异常则需要及时停药。
中药治疗方法:主要使用一些清热解毒的中药进行局部,由于足癣的病因是由真菌感染,所以单纯的中药抗真菌作用不明显,所以疗效欠佳,特别是反复性、顽固性足癣。
所以,目前无论西药,还是中药对于足癣,特别是顽固性足癣的治疗均不甚理想。
发明内容
本发明的目的在于揭示一种治疗足癣的药物组合物,并提出一种治疗复发性、顽固性足癣有着显著的临床疗效的药物组合物,以提高对足癣的治疗效果,并缓解因足癣所产生的足部异味及对生活的影响,并能有效降低药物对人体造成的毒副作用。
为实现上述发明目的,本发明提供了一种治疗足癣的药物组合物,各个组份的质量份数之和为100份,由以下组份组成:
唑类抗真菌药物0.5-5份、土荆皮0.1-10份、苦参0.1-10份、黄精0.1-10份、白鲜皮0.1-5份、薄荷0.1-5份、丁香0.1-2份、艾叶0.1-2份、明矾0.1-2份,余量为辅料和水。
作为本发明的进一步改进,唑类抗真菌药物选泊沙康唑、克霉唑、咪康唑、益康唑、联苯苄唑、酮康唑、伊曲康唑中的一种或者两种以上任意比例的混合物。
作为本发明的进一步改进,各个组份的质量份数之和为100份,由以下组份组成:
泊沙康唑1-3份、土荆皮0.5-5份、苦参0.5-5份、黄精0.5-5份、白鲜皮0.5-3份、薄荷0.5-3份、丁香0.5-2份、艾叶0.5-2份、明矾0.5-2份,余量为辅料和水。
作为本发明的进一步改进,该组合物还包括促渗剂0.1-1份,所述促渗剂选自丙二醇、氮酮、冰片中的一种或者两种以上任意比例的混合物。
作为本发明的进一步改进,所述药物组合物为液体制剂、半固体制剂或者固体制剂。
作为本发明的进一步改进,所述液体制剂包括喷雾剂;所述半固体制剂包括凝胶剂、软膏剂;所述固体制剂包括散剂。
与现有技术相比,本发明的有益效果是:在本发明中,实现了在抗真菌药物与中药共同配合作用下,既能发挥西药的抗真菌作用,又能发挥中药的祛湿、抑菌的作用,对足癣的治疗达到事半功倍的作用,所选用的西药具有抗真菌作用,而中药能够祛湿抑菌,从而能够标本兼治,尤其是在治疗复发性足癣有着显著的临床疗效,并具有制备简单、成本低的优点,使用方便,同时也能够有效降低免疫抑制剂对人体所造成的副作用。
具体实施方式
下面结合各实施方式对本发明进行详细说明,但应当说明的是,这些实施方式并非对本发明的限制,本领域普通技术人员根据这些实施方式所作的功能、方法、或者结构上的等效变换或替代,均属于本发明的保护范围之内。
经过试验证明,足癣是由真菌感染而得,尤其是反复性足癣,多是由真菌反复感染,但是从中医的角度来说一般情况下由真菌感染的足癣多与自身的情况相关,中医认为由体湿下注而易发感染真菌,从而引发足癣。本申请由抗真菌药物结合中药,从而可以达到杀菌、祛湿,标本兼治,同时制成各种形式的制剂,对足癣,尤其是对反复性足癣治疗效果确切,并且采用局部外用的给药方式降低了抗真菌药物所产生的毒副作用。
如无特殊说明,本说明书各实施例中的术语“室温”具体为23℃;术语“h”具体为时间计量单位:小时;术语“min”具体为时间计量单位:分钟;术语“ml”具体为体积单位:毫升(ml);术语“L”具体为体积单位:升;术语“浓度”具体为质量百分比浓度。
实施例1
本实施例公开了本发明一种治疗足癣的药物组合物的一种实施例。在本实施例中,公开了一种局部喷雾剂,该喷雾剂由以下组份组成:
成分 | 用量 |
泊沙康唑 | 0.1g |
土荆皮 | 0.1g |
苦参 | 0.1g |
黄精 | 0.1g |
白鲜皮 | 0.1g |
薄荷 | 0.1g |
丁香 | 0.1g |
艾叶 | 0.1g |
明矾 | 0.1g |
乙醇 | 150ml |
丙二醇 | 60ml |
吐温-80 | 5ml |
香精 | 适量 |
制备工艺:
将处方量的土荆皮、苦参、黄精、白鲜皮、薄荷、丁香、艾叶加水适量煮沸30分钟,放冷、滤过,弃去杂质,留上清液备用。
将明矾、香精用适量的乙醇水溶液溶解,然后加入丙二醇、吐温-80搅拌均匀,置入容器中,混合均匀。
再加入上述中药煎煮液,搅拌混合均匀,加水至1000ml。
将上述溶液灌装至喷瓶中,即得喷雾剂。
实施例2
本实施例公开了本发明一种治疗足癣的药物组合物的另一种实施例。本实施例公开了一种局部喷雾剂,该喷雾剂由以下组份组成:
成分 | 用量 |
泊沙康唑 | 5g |
土荆皮 | 10g |
苦参 | 10g |
黄精 | 10g |
白鲜皮 | 5g |
薄荷 | 5g |
丁香 | 5g |
艾叶 | 2g |
明矾 | 2g |
乙醇 | 150ml |
冰片 | 0.5g |
丙二醇 | 60ml |
吐温-80 | 5ml |
香精 | 适量 |
制备工艺:
将处方量的土荆皮、苦参、黄精、白鲜皮、薄荷、丁香、艾叶加水适量煮沸30分钟,放冷、滤过,弃去杂质,留上清液备用。
将明矾、冰片、香精用适量的乙醇水溶液溶解,然后加入丙二醇、吐温-80搅拌均匀,置入容器中,混合均匀。
再加入上述中药煎煮液,搅拌混合均匀,加水至1000ml。
将上述溶液灌装至喷瓶中,即得喷雾剂。
实施例3
本实施例公开了本发明一种治疗足癣的药物组合物的另一种实施例。本实施例公开了一种局部软膏剂,该软膏剂由以下组份组成:
制备工艺:
将处方量的土荆皮、苦参、黄精、白鲜皮、薄荷、丁香、艾叶加水适量煮沸30分钟,放冷、滤过,弃去杂质,上清液浓缩成膏状,备用。
将明矾、香精加入处方量的丙二醇、甘油、氮酮、羟苯乙酯,加入适量的水,搅拌均匀,备用。
将浓缩膏加入硬脂酸甘油酯、液体石蜡、白凡士林搅拌均匀,然后加入上述溶液中,边加边搅拌,直至混合均匀。
将上述膏状制剂灌装至软管中,即得软膏剂。
实施例4
本实施例公开了本发明一种治疗足癣的药物组合物的另一种实施例。本实施例公开了一种局部凝胶剂,该凝胶剂由以下组份组成:
制备工艺:
将处方量的土荆皮、苦参、黄精、白鲜皮、薄荷、丁香、艾叶加水适量煮沸30分钟,放冷、滤过,弃去杂质,上清液浓缩成膏状,备用。
将明矾、香精加入处方量的丙二醇、甘油、羟苯乙酯,加入适量的水,搅拌均匀,备用。
将卡波姆加入到适量的水中,搅拌溶解,后加入上述膏状中药浓缩液和韩促渗剂的溶液,边加边搅拌,直至混合均匀,用氢氧化钠溶液调节pH值至中性。
将上述膏状制剂灌装至软管中,即得凝胶剂。
实施例5
本实施例公开了本发明一种治疗足癣的药物组合物的另一种实施例。本实施例公开了一种局部凝胶剂,该凝胶剂由以下组份组成:
成分 | 用量 |
伊曲康唑 | 1g |
土荆皮 | 3g |
苦参 | 3g |
黄精 | 3g |
白鲜皮 | 2g |
薄荷 | 2g |
丁香 | 2g |
艾叶 | 0.5g |
明矾 | 0.5g |
卡波姆 | 20g |
甘油 | 100g |
丙二醇 | 50ml |
羟苯乙酯 | 1g |
香精 | 适量 |
纯化水 | 加至1000g |
制备工艺:
将处方量的土荆皮、苦参、黄精、白鲜皮、薄荷、丁香、艾叶加水适量煮沸30分钟,放冷、滤过,弃去杂质,上清液浓缩成膏状,备用。
将明矾、香精加入处方量的丙二醇、甘油、羟苯乙酯,加入适量的水,搅拌均匀,备用。
将卡波姆加入到适量的水中,搅拌溶解,后加入上述膏状中药浓缩液和韩促渗剂的溶液,边加边搅拌,直至混合均匀,用氢氧化钠溶液调节pH值至中性。
将上述膏状制剂灌装至软管中,即得凝胶剂。
实施例6
本实施例公开了本发明一种治疗足癣的药物组合物的另一种实施例。本实施例公开了一种散剂,该散剂由以下组份组成:
成分 | 用量 |
泊沙康唑 | 1g |
土荆皮 | 3g |
苦参 | 3g |
黄精 | 3g |
白鲜皮 | 2g |
薄荷 | 2g |
丁香 | 2g |
艾叶 | 0.5g |
明矾 | 0.5g |
冰片 | 0.5g |
滑石粉 | 100g |
制备工艺:
将处方量的土荆皮、苦参、黄精、白鲜皮、薄荷、丁香、艾叶加水适量煮沸30分钟,放冷、滤过,弃去杂质,上清液浓缩成膏状,然后干燥后粉碎,备用。
然后将明矾、冰片粉碎成细分,加入上述干粉,后加入泊沙康唑,最后与滑石粉混合均匀,用药用复合膜袋封装,即得。
上文所列出的一系列的详细说明仅仅是针对本发明的可行性实施方式的具体说明,它们并非用以限制本发明的保护范围,凡未脱离本发明技艺精神所作的等效实施方式或变更均应包含在本发明的保护范围之内。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (8)
1.一种治疗足癣的药物组合物,各个组份的质量份数之和为100份,其特征在于,由以下组份组成:
唑类抗真菌药物0.5-5份、土荆皮0.1-10份、苦参0.1-10份、黄精0.1-10份、白鲜皮0.1-5份、薄荷0.1-5份、丁香0.1-2份、艾叶0.1-2份、明矾0.1-2份,余量为辅料和水。
2.根据权利要求1所述的药物组合物,其特征在于,所述唑类抗真菌药物选泊沙康唑、克霉唑、咪康唑、益康唑、联苯苄唑、酮康唑、伊曲康唑中的一种或者两种以上任意比例的混合物。
3.根据权利要求1所述的药物组合物,其特征在于,各个组份的质量份数之和为100份,由以下组份组成:
唑类抗真菌药物1-3份、土荆皮0.5-5份、苦参0.5-5份、黄精0.5-5份、白鲜皮0.5-3份、薄荷0.5-3份、丁香0.5-2份、艾叶0.5-2份、明矾0.5-2份,余量为辅料和水。
4.根据权利要求1或3所述的药物组合物,其特征在于,还包括促渗剂0.1-1份,所述促渗剂选自丙二醇、氮酮、冰片中的一种或者两种以上任意比例的混合物。
5.根据权利要求1或3所述的药物组合物,其特征在于,所述药物组合物为液体制剂、半固体制剂或者固体制剂。
6.根据权利要求5所述的药物组合物,其特征在于,所述液体制剂包括喷雾剂。
7.根据权利要求5所述的药物组合物,其特征在于,所述半固体制剂包括凝胶剂、软膏剂。
8.根据权利要求5所述的药物组合物,其特征在于,所述固体制剂包括散剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811455140.2A CN109316552A (zh) | 2018-11-30 | 2018-11-30 | 一种治疗足癣的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811455140.2A CN109316552A (zh) | 2018-11-30 | 2018-11-30 | 一种治疗足癣的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109316552A true CN109316552A (zh) | 2019-02-12 |
Family
ID=65255972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811455140.2A Pending CN109316552A (zh) | 2018-11-30 | 2018-11-30 | 一种治疗足癣的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109316552A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112807353A (zh) * | 2021-02-22 | 2021-05-18 | 广东同德药业有限公司 | 一种硝酸益康唑喷雾剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111984A (zh) * | 1995-04-26 | 1995-11-22 | 广东医学院医药科技开发中心 | 一组具有消炎、止痒、抗菌作用的外用浴剂 |
KR20100135452A (ko) * | 2009-06-17 | 2010-12-27 | 김진훈 | 무좀 치료 조성물 |
CN103027437A (zh) * | 2010-05-21 | 2013-04-10 | 张红雨 | 一种保健鞋垫 |
CN107397777A (zh) * | 2017-08-19 | 2017-11-28 | 杨天梅 | 一种湿袜 |
-
2018
- 2018-11-30 CN CN201811455140.2A patent/CN109316552A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111984A (zh) * | 1995-04-26 | 1995-11-22 | 广东医学院医药科技开发中心 | 一组具有消炎、止痒、抗菌作用的外用浴剂 |
KR20100135452A (ko) * | 2009-06-17 | 2010-12-27 | 김진훈 | 무좀 치료 조성물 |
CN103027437A (zh) * | 2010-05-21 | 2013-04-10 | 张红雨 | 一种保健鞋垫 |
CN107397777A (zh) * | 2017-08-19 | 2017-11-28 | 杨天梅 | 一种湿袜 |
Non-Patent Citations (3)
Title |
---|
会员37821507、蔡先萌: "脚癣怎么治都好几年了看不好", 《HTTP://CLUB.XYWY.COM/STATIC/20140616/45961588.HTM,脚癣怎么治都好几年了看不好》 * |
徐亚珍、许小杰: "浅谈泡足保健治病", 《保健防病》 * |
陈洁: "《临床皮肤性病综合诊疗学》", 30 June 2017, 吉林科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112807353A (zh) * | 2021-02-22 | 2021-05-18 | 广东同德药业有限公司 | 一种硝酸益康唑喷雾剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1201723C (zh) | 皮肤与组织护理和/或治疗制剂及其应用 | |
Louw et al. | Medicinal bulbous plants of South Africa and their traditional relevance in the control of infectious diseases | |
CN100512835C (zh) | 一种防治兔、鸡球虫病的中草药缓释注射剂及其制备方法 | |
Neena et al. | An ancient herb aloevera in dentistry: A review | |
KR20070054222A (ko) | 진통 작용이 있는 약제 조성물 | |
CN107970275A (zh) | 一种治疗手足癣的外用药剂 | |
KR101066676B1 (ko) | 경구용 피부 미용 개선용 조성물 | |
CN102349608A (zh) | 一种清咽润喉的保健品组合物及其制备方法 | |
CN109316552A (zh) | 一种治疗足癣的药物组合物 | |
CN104825554A (zh) | 一种治疗痛风性关节炎的喷雾剂 | |
EP3884942B1 (en) | Use of bulleyaconitine a for treating skin disorders | |
WO2021217788A1 (zh) | 一种复合型保肝解酒片的制备方法 | |
CN103655735B (zh) | 一种治疗脚气、皮肤瘙痒症泡洗剂 | |
CN103330813A (zh) | 治疗脚气的中药组合物 | |
US20190160126A1 (en) | Compositions and methods for treating reproductive indicators symptomatic of male infertility | |
CN101337026A (zh) | 一种治疗痛风的外用药物组合物 | |
WO2019142042A1 (en) | Synergistic medicinal preparation for treating skin disorders like tinea versicolor | |
CN109498728A (zh) | 一种抗真菌中药组合物及其制备方法和应用 | |
JPS5913726A (ja) | セリ濃縮物を主成分とする食品 | |
CN105288107B (zh) | 复方沙棘清咽组合物及其制备方法 | |
CN108355138A (zh) | 一种氮酮在药物透皮促渗中的应用 | |
AU2006203630B2 (en) | Intramammary formulations | |
CN107929624A (zh) | 一种治疗脚气的药膏及其制备方法 | |
RU2160596C1 (ru) | Сбор лекарственных растений, обладающий противовирусным, противомикробным и иммуномодулирующим действиями | |
US20080050456A1 (en) | Intramammary formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190212 |
|
RJ01 | Rejection of invention patent application after publication |